Abstract:Introduction: In mitochondrial DNA (mtDNA) depletion syndrome (MDS), patients cannot maintain sufficient mtDNA for their energy needs. MDS presentations range from infantile encephalopathy with hepatopathy (Alpers syndrome) to adult chronic progressive external ophthalmoplegia. Most are caused by nucleotide imbalance or by defects in the mtDNA replisome. There is currently no curative treatment available. Nucleoside therapy is a promising experimental treatment for TK2 deficiency, where patients are supplemented with exogenous deoxypyrimidines. We aimed to explore the benefits of nucleoside supplementation in POLG and TWNK deficient fibroblasts. Methods: We used high-content fluorescence microscopy with software-based image analysis to assay mtDNA content and membrane potential quantitatively, using vital dyes PicoGreen and MitoTracker Red CMXRos respectively. We tested the effect of 15 combinations (A, T, G, C, AT, AC, AG, CT, CG, GT, ATC, ATG, AGC, TGC, ATGC) of deoxynucleoside supplements on mtDNA content of fibroblasts derived from four patients with MDS (POLG1, POLG2, DGUOK, TWNK) in both a replicating (10% dialysed FCS) and quiescent (0.1% dialysed FCS) state. We used qPCR to measure mtDNA content of supplemented and non-supplemented fibroblasts following mtDNA depletion using 20 μM ddC and after 14- and 21-day recovery in a quiescent state. Results: Nucleoside treatments at 200 μM that significantly increased mtDNA content also significantly reduced the number of cells remaining in culture after 7 days of treatment, as well as mitochondrial membrane potential. These toxic effects were abolished by reducing the concentration of nucleosides to 50 μM. In POLG1 and TWNK cells the combination of ATGC treatment increased mtDNA content the most after 7 days in non-replicating cells. ATGC nucleoside combination significantly increased the rate of mtDNA recovery in quiescent POLG1 cells following mtDNA depletion by ddC. Conclusion: High-content imaging enabled us to link mtDNA copy number with key read-outs linked to patient wellbeing. Elevated G increased mtDNA copy number but severely impaired fibroblast growth, potentially by inhibiting purine synthesis and/or causing replication stress. Combinations of nucleosides ATGC, T, or TC, benefited growth of cells harbouring POLG mutations. These combinations, one of which reflects a commercially available preparation, could be explored further for treatment of POLG patients.

Quantitative evaluation of the mitochondrial DNA depletion syndrome

Detection of large deletions in mitochondrial DNA during skin aging

Detection and Quantification of Large Scale Deletions of Human Mitochondrial DNA by Real‐time PCR

Large mitochondrial DNA deletions in ultraviolet B-induced cutaneous photodamage

Diagnostic value of succinate ubiquinone reductase activity in the identification of patients with mitochondrial DNA depletion

Mitochondrial DNA depletion syndrome: new descriptions and the use of citrate synthase as a helpful tool to better characterise the patients

Decoding the mitochondria without a code: mechanistic insights into mitochondrial DNA depletion syndromes

Quantitation of mitochondrial DNA in human lymphoblasts by a competitive polymerase chain reaction method: application to the study of inhibitors of mitochondrial DNA content.

Nucleoside supplements as treatments for mitochondrial DNA depletion syndrome

Heteroplasmy Detection of Mitochondrial DNA A3243G Mutation Using Quantitative Real-Time PCR Assay Based on TaqMan-MGB Probes

Quantitative analysis of mitochondrial DNA 4977-bp deletion in sporadic breast cancer and benign breast diseases

Guanylate Kinase 1 Deficiency: A Novel and Potentially Treatable Mitochondrial DNA Depletion/Deletions Disease

Liver mtDNA content increases during development: a comparison of methods and the importance of age- and tissue-specific controls for the diagnosis of mtDNA depletion

[Phenotype and genotype of twelve Chinese children with mitochondrial DNA depletion syndromes]

Application of dual-genome oligonucleotide array-based comparative genomic hybridization to the molecular diagnosis of mitochondrial DNA deletion and depletion syndromes

Bioenergetic consequences of accumulating the common 4977-bp mitochondrial DNA deletion

Quantitative analysis of mitochondrial DNA 4977-bp deletion in sporadic breast cancer and benign breast tumor

Detection Mitochondrial DNA A3243G Mutation Loads by the Real-Time Amplification Refractory Mutation System Quantitative Polymerase Chain Reaction

Quantitative Abnalysis if Mittochondraial DNA Deletions in Myocardial Biopsy Samples Form Patients with Viral Myocarditis and Dilated Cardlimyopathy

Deletion of A 4977-Bp Fragment in the Mitochondrial Genome is Associated with Mitochondrial Disease Severity

Severe depletion of mitochondrial DNA in spinal muscular atrophy